Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 36, Issue 7 p. 831-831 CORRIGENDAFree Access The Risk of Glioblastoma with TNF Inhibitors This article corrects the following: The Risk of Glioblastoma with TNF Inhibitors Michael Guo, Hao Luo, Ali Samii, Mahyar Etminan, Volume 36Issue 4Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy pages: 449-454 First Published online: April 13, 2016 First published: 21 July 2016 https://doi.org/10.1002/phar.1789AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Guo et al.,1 incorrect number of cases and reporting odds ratios (ROR) have been published in Abstract and Results section, respectively. Abstract, page 449 RESULTS We identified 81 cases of GBM or GBM-M with adalimumab in the U.S. FDA FAERS and 49 cases in the WHO drug monitoring database. For infliximab, 40 and 32 cases were identified in the FAERS and WHO databases, respectfully. Infliximab had the highest association with GBM (WHO: ROR = 7.41 (5.19–10.57), FAERS: ROR = 2.80 [1.89–4.15]). Adalimumab was also highly associated with GBM (WHO: ROR = 3.54 [2.58–4.89], FAERS: ROR = 1.99 [1.41–2.80]). Here is the correct text: RESULTS We identified 35 cases of GBM or GBM-M with adalimumab in the U.S. FDA FAERS and 39 cases in the WHO drug monitoring database. For infliximab, 26 and 32 cases were identified in the FAERS and WHO databases, respectfully. Infliximab had the highest association with GBM (WHO: ROR = 7.41 (5.19–10.57), FAERS: ROR = 2.80 [1.89–4.15]). Adalimumab was also highly associated with GBM (WHO: ROR = 3.54 [2.58–4.89], FAERS: ROR = 1.99 [1.41–2.80]). Results section, page 451 (3rd sentence) Infliximab had the highest association with GBM/GBM-M (WHO: ROR = 7.41 95% CI [5.19–10.57], FAERS: ROR = 3.80 95% CI [1.41–2.80]). Here is the correct text: Results section, page 451 (3rd sentence) Infliximab had the highest association with GBM/GBM-M (WHO: ROR = 7.41 95% CI [5.19–10.57], FAERS: ROR = 2.80 95% CI [1.89–4.15]). We apologize for these errors. Reference 1Guo M, Luo H, Samii A, Etminan M. The risk of glioblastoma with TNF inhibitors. Pharmacotherapy 2016; 36(4): 449– 54. Volume36, Issue7July 2016Pages 831-831 ReferencesRelatedInformation